ClinicalTrials.gov
ClinicalTrials.gov Menu

Once a Day (QD) - Twice a Day (BID) Clinical Trial: Didanosine, Lamivudine and Efavirenz Versus Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of HIV

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00256828
Recruitment Status : Completed
First Posted : November 22, 2005
Last Update Posted : October 16, 2007
Sponsor:
Information provided by:
Clinical Trial Agency of HIV Study Group

Brief Summary:
The purpose of this study is to compare the antiviral activity of two treatment groups for HIV chronic infection: a QD regimen of didanosine, lamivudine and efavirenz versus a BID regimen of zidovudine, lamivudine and efavirenz. Both will be administered with food in the starting treatment of human immunodeficiency virus infection at Week 48.

Condition or disease Intervention/treatment Phase
HIV Infections Drug: didanosine + lamivudine + efavirenz Phase 4

  Show Detailed Description

Study Type : Interventional  (Clinical Trial)
Enrollment : 360 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open Label, Clinical Trial Comparing a QD Regimen of Didanosine, Lamivudine and Efavirenz With a Standard BID Regimen of Zidovudine, Lamivudine and Efavirenz in the Starting Treatment of Human Immunodeficiency Virus Infection (GESIDA 39/03)
Study Start Date : June 2004
Study Completion Date : November 2006

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS




Primary Outcome Measures :
  1. Percentage of patients with HIV-RNA levels < 50 c/ml (intent-to-treat [ITT])

Secondary Outcome Measures :
  1. Percentage of patients with HIV-RNA level < 400 c/ml
  2. Time to therapy failure
  3. CD4 cell count increase from Baseline to Week 48 (w48)
  4. Quality of life changes
  5. Compliance to both treatment regimens
  6. Description of adverse events


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Chronic HIV infection with plasma RNA viral burden of HIV > 2,000 copies/ml obtained in the month prior to randomization.
  • Ages 18 years or older.
  • Women with childbearing potential should use an effective contraceptive method.
  • The subjects should give their written informed consent.
  • The subjects should provide the baseline laboratory values measured during the 4 weeks prior to the start of the study drugs, specified below:

    • serum creatinine < 1.5 times the upper normal limit;
    • total amylase < 1.4 times the upper normal limit;
    • liver enzymes (AST, ALT) < 4 times the upper normal limit.

Exclusion Criteria:

  • Previous antiretroviral treatment.
  • Suspected (acute) primary HIV infection starting less than six months before.
  • Suspected or proven acute hepatitis in the 30 days prior to inclusion in the study. Subjects with chronic hepatitis are eligible provided their liver function enzymes < 4 times the upper normal limit.
  • Previous therapy with agents with a significant potential of systemic myelosuppression, neurotoxicity, pancreatotoxicity, liver toxicity or cytotoxicity in the 3 months prior to the start of the study, or expected need for requiring therapy on inclusion, or therapy with methadone or ribavirin/interferons or treatment with neurotoxic drugs or drugs affecting CYP 3A4.
  • Patients under methadone program
  • Abuse of alcohol or drugs, sufficient, in the investigator's opinion, to prevent an adequate compliance with the study treatment or that could increase the risk of developing pancreatitis or toxic hepatitis.
  • Untreatable diarrhea (> 6 loose stools/day for at least 7 consecutive days) within the 30 days prior to inclusion in the study.
  • Pregnancy or nursing.
  • History of bilateral peripheral neuropathy or signs and symptoms of bilateral peripheral neuropathy > Grade 2 on screening.
  • Inability to tolerate oral drugs.
  • Any other clinical condition or previous therapy that, in the investigator's opinion, leads the patient to be inadequate for the study or unable to comply with the dosage requirements.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00256828


  Show 57 Study Locations
Sponsors and Collaborators
Clinical Trial Agency of HIV Study Group
Investigators
Study Chair: Juan Berenguer Berenguer, MD Hospital Gregorio Marañón

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
ClinicalTrials.gov Identifier: NCT00256828     History of Changes
Other Study ID Numbers: GESIDA-3903
First Posted: November 22, 2005    Key Record Dates
Last Update Posted: October 16, 2007
Last Verified: November 2005

Keywords provided by Clinical Trial Agency of HIV Study Group:
HIV infection
Highly active antiretroviral therapy
Treatment Naive

Additional relevant MeSH terms:
Infection
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
Lamivudine
Efavirenz
Zidovudine
Didanosine
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents
Cytochrome P-450 CYP2C9 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Cytochrome P-450 CYP2C19 Inhibitors
Cytochrome P-450 CYP2B6 Inducers
Cytochrome P-450 Enzyme Inducers
Cytochrome P-450 CYP3A Inducers